{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:04:01Z","timestamp":1789632241353,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The use of venetoclax in combination with hypomethylating agents (HMAs) has become a standard treatment approach for both newly diagnosed and relapsed\/refractory (R\/R) AML patients who are ineligible for intensive chemotherapy. We aimed to share the real-life data of this combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective study included 38 patients with newly diagnosed or R\/R AML who received at least one cycle of venetoclax-HMA combination therapy between July 2018 and August 2025. Response status, survival rates, and the incidence of hematological adverse events were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve patients (31.6%) were treatment-naive, while the remaining 26 (68.4%) were R\/R AML. The median age of all patients was 67, and 57.9% were male. 23.7% of the patients were in the poor-risk group. The overall response rate (ORR) was 73.7% in the entire cohort, and 83.3% and 69.2% in the first-line and R\/R groups, respectively. No statistically significant difference in ORR was observed between the newly diagnosed and R\/R groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.453); however, given the small sample sizes \u2014 particularly in the newly diagnosed arm (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) \u2014 this study was insufficiently powered to detect or exclude a clinically meaningful difference between groups. The restricted mean progression-free survival (RMST-PFS) was 18.35 months (95% CI 15.16\u201321.22), and the restricted mean overall survival (RMST-OS) was 21.12 months (95% CI 19.03\u201322.86). As adverse events, grade 3 or higher neutropenia was 39.5% and thrombocytopenia was 31.6%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-center real-world experience, venetoclax-HMA combination therapy demonstrated response rates and a toxicity profile consistent with those reported in larger studies, supporting its feasibility in routine clinical practice for AML patients ineligible for intensive chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16560-8","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:04:42Z","timestamp":1784210682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience"],"prefix":"10.1186","volume":"26","author":[{"given":"K\u00fcbra","family":"Oral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"12","key":"16560_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184.","journal-title":"N Engl J Med"},{"issue":"12","key":"16560_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33453","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the SEER database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361. https:\/\/doi.org\/10.1002\/cncr.33453.","journal-title":"Cancer"},{"issue":"1","key":"16560_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.26370","volume":"97","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97(1):68\u201378. https:\/\/doi.org\/10.1002\/ajh.26370.","journal-title":"Am J Hematol"},{"issue":"3","key":"16560_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood. 2015;126(3):291\u20139. https:\/\/doi.org\/10.1182\/blood-2015-01-621664.","journal-title":"Blood"},{"issue":"15","key":"16560_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384. https:\/\/doi.org\/10.1200\/JCO.18.01600.","journal-title":"J Clin Oncol"},{"key":"16560_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","volume":"8","author":"CM Adams","year":"2019","unstructured":"Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 2019;8:636. https:\/\/doi.org\/10.3389\/fonc.2018.00636.","journal-title":"Front Oncol"},{"issue":"11","key":"16560_CR7","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81(11):3091\u20136. https:\/\/doi.org\/10.1182\/blood.V81.11.3091.3091.","journal-title":"Blood"},{"issue":"6","key":"16560_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378. https:\/\/doi.org\/10.1016\/S1470-2045(16)30019-5.","journal-title":"Lancet Oncol"},{"issue":"22","key":"16560_CR9","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. Blood. 2017;130(22):2392\u2013400. https:\/\/doi.org\/10.1182\/blood-2017-06-788786.","journal-title":"Blood"},{"issue":"7","key":"16560_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"4","key":"16560_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"16560_CR12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Institutes of Health. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment."},{"issue":"18","key":"16560_CR13","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/cancers15184618","volume":"15","author":"A Ucciero","year":"2023","unstructured":"Ucciero A, Pagnoni F, Scotti L, Pisterna A, Barone-Adesi F, Gaidano G, et al. Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies. Cancers (Basel). 2023;15(18):4618. https:\/\/doi.org\/10.3390\/cancers15184618.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"16560_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4274\/tjh.galenos.2024.2024.0436","volume":"42","author":"TA K\u0131rk\u0131zlar","year":"2025","unstructured":"K\u0131rk\u0131zlar TA, \u00d6zkocaman V. Antifungal prophylaxis in the treatment combination of hypomethylating agents and venetoclax for AML: A survey study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology. Turk J Hematol. 2025;42(1):69\u201371. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0436.","journal-title":"Turk J Hematol"},{"issue":"7","key":"16560_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/cncr.34585","volume":"129","author":"E Todisco","year":"2023","unstructured":"Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, et al. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992\u20131004. https:\/\/doi.org\/10.1002\/cncr.34585.","journal-title":"Cancer"},{"issue":"7","key":"16560_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.26188","volume":"96","author":"A Apel","year":"2021","unstructured":"Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, et al. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021;96(7):790\u20135. https:\/\/doi.org\/10.1002\/ajh.26188.","journal-title":"Am J Hematol"},{"key":"16560_CR17","doi-asserted-by":"publisher","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","volume":"114","author":"E De Bellis","year":"2022","unstructured":"De Bellis E, Imbergamo S, Candoni A, Li\u00e7o A, Tanasi I, Mauro E, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leuk Res. 2022;114:106803. https:\/\/doi.org\/10.1016\/j.leukres.2022.106803.","journal-title":"Leuk Res"},{"issue":"4","key":"16560_CR18","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","volume":"5","author":"J Feld","year":"2021","unstructured":"Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. Hemasphere. 2021;5(4):e549. https:\/\/doi.org\/10.1097\/HS9.0000000000000549.","journal-title":"Hemasphere"},{"issue":"24","key":"16560_CR19","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021004977","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2021004977.","journal-title":"Blood Adv"},{"issue":"22","key":"16560_CR20","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024021234","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J, Xue SL, Wang Y, He XF, Hu XH, Miao M, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145(22):2645\u201355. https:\/\/doi.org\/10.1182\/blood.2024021234.","journal-title":"Blood"},{"issue":"5","key":"16560_CR21","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003397","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5(5):1552\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2020003397.","journal-title":"Blood Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16560-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16560-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16560-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:20:32Z","timestamp":1789629632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16560-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16560"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16560-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics committee approval was obtained from the F\u0131rat University Non-Interventional Scientific Research Ethics Committee (Decision No: 2025\/04\u201317, Date: 27\/02\/2025). All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki. The requirement for informed consent was waived owing to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1106"}}